Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
The key inclusion and exclusion criteria include but are not limited to the following:~Inclusion Criteria:~* Has underlying chronic conditions but assessed to be stable as per investigator~* Has ability to complete electronic Vaccine Report Card (eVRC) data collection without assistance as per investigator~Exclusion Criteria:~* Has a history of invasive pneumococcal disease (IPD) or other culture-positive pneumococcal disease ≤3 years before Visit 1 (Day 1)~* Has a known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease~* Has a coagulation disorder contraindicating intramuscular vaccination~* Has a recent illness with fever~* Has a known malignancy that is progressing or has required active treatment \<3 years before enrollment~* Is expected to receive any pneumococcal vaccine during the study outside of the protocol~* Has received systemic corticosteroids for ≥14 consecutive days and has not completed treatment ≥14 days before receipt of study vaccine~* Is currently receiving immunosuppressive therapy, including chemotherapeutic agents or other immunotherapies/immunomodulators used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease~* Has received any non-live vaccine ≤14 days before receipt of study vaccine or is scheduled to receive any non-live vaccine ≤30 days after receipt of study vaccine~* Has received any live vaccine ≤30 days before receipt of study vaccine or is scheduled to receive any live vaccine ≤30 days after receipt of study vaccine~* Has received a blood transfusion or blood products, including immunoglobulins ≤6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product ≤30 days after receipt of study vaccine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- V116 Lot 1 (Type: EXPERIMENTAL): Participants will receive a single 0.5 mL intramuscular (IM) dose of V116 Lot 1 on Day 1.
- V116 Lot 2 (Type: EXPERIMENTAL): Participants will receive a single 0.5 mL IM dose of V116 Lot 2 on Day 1.
- V116 Lot 3 (Type: EXPERIMENTAL): Participants will receive a single 0.5 mL IM dose of V116 Lot 3 on Day 1.
- PPSV23 (Type: ACTIVE_COMPARATOR): Participants will receive a single 0.5 mL IM dose of PPSV23 on Day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).